Drug Approval | December 28, 2021
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
It plans to deliver over 300 million doses to the Indian government
It plans to deliver over 300 million doses to the Indian government
The Home Healthcare market is expected to be US $ 14.2 by 2025
Flattish volume growth and subdued new launches were key factors for last month
The hospital has recently launched Radionuclide therapy
He has over 22 years of experience in pharmaceutical sales & business development
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The NMPA approval is based on the positive data of GEMSTONE-302 study, a multi-center, randomized, double-blind, phase III study that evaluated the efficacy and safety of Cejemly or placebo in combination with chemotherapy in first-line stage IV NSCLC patients
Subscribe To Our Newsletter & Stay Updated
